PMID- 24668895
OWN - NLM
STAT- MEDLINE
DCOM- 20150212
LR  - 20220311
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Print)
IS  - 2045-7634 (Linking)
VI  - 3
IP  - 3
DP  - 2014 Jun
TI  - Comparison of HER2 expression between primary colorectal cancer and their 
      corresponding metastases.
PG  - 674-80
LID - 10.1002/cam4.228 [doi]
AB  - The aim of this study was to compare human epidermal growth factor 2 (HER2) 
      status in primary colorectal cancer and paired liver or lung metastasis. Gene 
      amplification of HER2 has been intensively evaluated in contemporary oncology, 
      especially in breast and stomach cancer. The knowledge of HER2 status in primary 
      and metastatic sites may be of potential value for therapeutic decision making in 
      metastatic colon cancer. The HER2 status was assessed by fluorescence in situ 
      hybridization (FISH) and immunohistochemistry (IHC) in 94 colorectal cancer with 
      corresponding liver or lung metastases. HER2 amplification was present in 19 of 
      the 188 (10.1%) of both primary and metastases combined. Four (4.6%) patients 
      showed HER2 amplification in the metastasis and 10 (10.6%) patients showed HER2 
      amplification in the primary tumor. In 14 cases (14.8%), the HER2 status of the 
      primary lesions was different from that of the associated metastases. The 
      presence of HER2 overexpression in KRAS mutant colon cancer was found in 5.3%. No 
      relationship was found between HER2 expression and KRAS status (P = 0.486). The 
      evidence of HER2 positive metastatic lesion and primary colorectal cancer suggest 
      that HER2 assessment might be considered in selected cases when this may help 
      change the therapeutic decision.
CI  - (c) 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Lee, Won-Suk
AU  - Lee WS
AD  - Department of Surgery, Gil Medical Center, Gachon University, School of Medicine, 
      Incheon, Korea.
FAU - Park, Yeon Ho
AU  - Park YH
FAU - Lee, Jung Nam
AU  - Lee JN
FAU - Baek, Jeong-Heum
AU  - Baek JH
FAU - Lee, Tae-Hoon
AU  - Lee TH
FAU - Ha, Seung Yeon
AU  - Ha SY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140325
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (KRAS protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics
MH  - Colorectal Neoplasms/*genetics/pathology
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Liver Neoplasms/*genetics/pathology
MH  - Lung Neoplasms/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Proto-Oncogene Proteins/genetics
MH  - Proto-Oncogene Proteins p21(ras)
MH  - Receptor, ErbB-2/*biosynthesis/genetics
MH  - ras Proteins/genetics
PMC - PMC4101759
OTO - NOTNLM
OT  - Colon cancer
OT  - HER2
OT  - KRAS
OT  - metastasis
EDAT- 2014/03/29 06:00
MHDA- 2015/02/13 06:00
PMCR- 2014/06/01
CRDT- 2014/03/27 06:00
PHST- 2013/11/19 00:00 [received]
PHST- 2014/01/20 00:00 [revised]
PHST- 2014/01/27 00:00 [accepted]
PHST- 2014/03/27 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2015/02/13 06:00 [medline]
PHST- 2014/06/01 00:00 [pmc-release]
AID - 10.1002/cam4.228 [doi]
PST - ppublish
SO  - Cancer Med. 2014 Jun;3(3):674-80. doi: 10.1002/cam4.228. Epub 2014 Mar 25.